NL

VALHI REPORTS FIRST QUARTER 2024 RESULTS

Retrieved on: 
Jeudi, mai 9, 2024
Corporation, Chemical substance, Cyberattack, Titanium dioxide, Average cost, Safety, Health, Zinc, Biophysical environment, Gross domestic product, Insurance, Environment, Steel, VHI, Aluminium, Property, Government, Risk management

The Chemicals Segment’s net sales of $478.8 million in the first quarter of 2024 were $52.5 million, or 12%, higher than in the first quarter of 2023.

Key Points: 
  • The Chemicals Segment’s net sales of $478.8 million in the first quarter of 2024 were $52.5 million, or 12%, higher than in the first quarter of 2023.
  • The Chemicals Segment’s TiO2 sales volumes were 28% higher in the first quarter of 2024 as compared to the first quarter of 2023.
  • Average TiO2 selling prices were 11% lower in the first quarter of 2024 as compared to the first quarter of 2023.
  • TiO2 production volumes were 15% higher in the first quarter of 2024 compared to the first quarter of 2023.

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

Retrieved on: 
Jeudi, mai 9, 2024
Congress, American College, Investment, Risk, ASCVD, CVD, Research, Moyamoya disease, Research and development, Partnership, Conference, PCSK9, Hypercholesterolemia, History, Growth, Administration, Cardiology, Patient, Physician, LDL, Cardiovascular disease, NAMS, Standard of care, Phase 3, Clinical trial, Biomarker, Drug discovery, Partner, Pharmaceutical industry

-- Strong financial position; ending the quarter with $481.1 million in cash --

Key Points: 
  • Driven by strong patient and physician interest globally, NewAmsterdam extended enrollment to the end of April and randomized over 9,500 patients.
  • In January 2024, NewAmsterdam appointed William H. Lewis, J.D., M.B.A as Chair of its Board of Directors.
  • NewAmsterdam currently expects to achieve the following upcoming milestones:
    Announce topline data from the Phase 3 BROOKLYN trial for obicetrapib monotherapy in the third quarter of 2024.
  • Revenue: NewAmsterdam recognized $1.4 million in revenue for the quarter ended March 31, 2024, compared to $8.6 million in the same period in 2023.

VEON’s Banglalink Leads 3G Phase-out, Deepening its Focus on 4G

Retrieved on: 
Jeudi, mai 9, 2024
VEON, International Cricket Council, Speedtest.net, Euronext Amsterdam

The 3G phase out follows extensive investment by Banglalink in next generation 4G networks to provide high-quality nationwide connectivity and accelerate the use of digital services.

Key Points: 
  • The 3G phase out follows extensive investment by Banglalink in next generation 4G networks to provide high-quality nationwide connectivity and accelerate the use of digital services.
  • The operator is recognized for the provision of fastest 4G service in the country, winning the Ookla® Speedtest Award™ for four consecutive years.
  • “As Bangladesh’s Digital Operator, our goal is to deliver seamless connectivity and innovative services to our customers,“ explains Erik Aas, CEO of Banglalink.
  • “By reallocating more resources to 4G, we will take the customer experience to new heights and enhance our customers' 4G experiences.

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Jeudi, mai 9, 2024
MuSK protein, FDA, ARDA, IND, PDUFA, Medicine, Autoimmunity, Efgartigimod alfa, Glomerulonephritis, CMS, Inflammation, ITP, IIP, ALS, Alfa Romeo, C2, Therapy, Systemic scleroderma, Safety, Euronext, Nektar, DGF, Sjögren syndrome, CIDP, Biology, IL-6, Nektar Therapeutics, GMG, TED, File, MMN, Lupus nephritis, Kidney, AMR, Multifocal motor neuropathy, Patient, Congenital myasthenic syndrome, Immune system, Dermatomyositis, Growth, Amgen, Pharmaceutical industry

“The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • “We are driven by our commitment to provide patients with the broadest gMG product offering that consistently delivers on safety and efficacy.
  • VYVGART SC played a key role in our growth over the quarter, expanding the breadth of our prescriber base and reaching new patients.
  • In addition, argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS).

ProQR Announces First Quarter 2024 Operating and Financial Results

Retrieved on: 
Jeudi, mai 9, 2024
EON, Trident, Annual general meeting, Research, Partnership, Doctor of Philosophy, Webcast, Biomarker, Knowledge, Cholestasis, NTCP, RNA editing, Oncology, European Patent Convention, Oligonucleotide, Serum, Lilly, Eli Lilly and Company, Ribose, Pseudouridine, Poster, Alnylam Pharmaceuticals, Eli Lilly, RNA, Exercise, NHP, Clinical trial, ProQR, ADAR, B4GALT1, Adenosine, EDT, Science, Patent, Patient, Liver, Eon, Metabolism, Uridine, Q&A, Pharmaceutical industry

(Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2024, and provided a business update.
  • At March 31, 2024, ProQR held cash and cash equivalents and short term financial assets of €102.7 million, compared to €118.9 million cash and cash equivalents at December 31, 2023.
  • General and administrative costs were €3.5 million for the quarter ended March 31, 2024 compared to €4.0 million for the same period last year.
  • For further financial information for the period ended March 31, 2024, please refer to the Q1 financial report filing.

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Retrieved on: 
Mercredi, mai 8, 2024
FDA, CFO, Research, CRC, Partnership, PDAC, ASCO, CD137, AACR, Biomarker, EGFR, Lung cancer, Non-small-cell lung cancer, Drug design, Illinois State University, HER2, Food, Bristol Myers Squibb, Patent, Eli Lilly and Company, BLA, NRG1, Therapy, NSCLC, PYC, Safety, Cetuximab, Pembrolizumab, Marketing, Clinical trial, CD3, MET, HNSCC, Gilead Sciences, Betta, Epitope, Biologics license application, Patient, Antigen, Head, Pharmaceutical industry

Merus plans to provide updated efficacy, durability and safety data of this cohort in the second half of 2024.

Key Points: 
  • Merus plans to provide updated efficacy, durability and safety data of this cohort in the second half of 2024.
  • In 2024, Merus is planning to initiate the evaluation of petosemtamab with standard chemotherapy in 2L CRC.
  • During the first quarter of 2024, Merus achieved a milestone of $1 million for candidate nomination and expects to receive payment in the second quarter of 2024.
  • In March 2024, Merus and Gilead Sciences announced a collaboration to discover novel antibody based trispecific T-cell engagers using Merus’ patented Triclonics® platform.

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Mercredi, mai 8, 2024
FDA, Citizenship, Research and development, Attack, Food, EOP, Research, Book, Trial of the century, Conference, Administration, Hereditary angioedema, Record, Bank statement, HAE, Growth

Joan Schmidt, J.D., Chief Legal Officer of Pharvaris, has given notice of her resignation, effective June 1, 2024.

Key Points: 
  • Joan Schmidt, J.D., Chief Legal Officer of Pharvaris, has given notice of her resignation, effective June 1, 2024.
  • R&D expenses were €18.5 million for the quarter ended March 31, 2024, compared to €13.7 million for the quarter ended March 31, 2023.
  • G&A expenses were €9.8 million for the quarter ended March 31, 2024, compared to €7.3 million for the quarter ended March 31, 2023.
  • Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.

NL REPORTS FIRST QUARTER 2024 RESULTS

Retrieved on: 
Mercredi, mai 8, 2024
Corporation, Titanium dioxide, Safety, Health, Zinc, Gross domestic product, Hurricane Laura, Environment, NL Industries, Steel, Aluminium, Government, Interest, Risk management

Dallas, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- NL Industries, Inc. (NYSE: NL) today reported net income attributable to NL stockholders of $6.8 million, or $.14 per share, in the first quarter of 2024 compared to a net loss attributable to NL stockholders of $6.7 million, or $.14 per share, in the first quarter of 2023.

Key Points: 
  • Dallas, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- NL Industries, Inc. (NYSE: NL) today reported net income attributable to NL stockholders of $6.8 million, or $.14 per share, in the first quarter of 2024 compared to a net loss attributable to NL stockholders of $6.7 million, or $.14 per share, in the first quarter of 2023.
  • NL results include an unrealized gain of $2.4 million in the first quarter of 2024 related to the change in value of marketable equity securities compared to an unrealized loss of $5.5 million in the first quarter of 2023.
  • NL recognized equity in earnings of Kronos of $2.5 million in the first quarter of 2024 compared to equity in losses of Kronos of $4.6 million in the first quarter of 2023.
  • TiO2 sales volumes were 28% higher in the first quarter of 2024 as compared to the first quarter of 2023.

Weekly share repurchase program transaction details

Retrieved on: 
Mercredi, mai 8, 2024
Annual report, SBM Offshore, Opportunity, SBM, Risk

These statements may be identified by words such as ‘expect’, ‘should’, ‘could’, ‘shall’ and similar expressions.

Key Points: 
  • These statements may be identified by words such as ‘expect’, ‘should’, ‘could’, ‘shall’ and similar expressions.
  • The companies in which SBM Offshore N.V. directly and indirectly owns investments are separate legal entities.
  • In this release “SBM Offshore” and “SBM” are sometimes used for convenience where references are made to SBM Offshore N.V. and its subsidiaries in general.
  • "SBM Offshore®", the SBM logomark, “Fast4Ward®”, “emissionZERO®” and “Float4Wind®” are proprietary marks owned by SBM Offshore.

AMG Announces Results of the Annual General Meeting

Retrieved on: 
Mercredi, mai 8, 2024
Annual general meeting, Retirement, Supervisory board

Amsterdam, 8 May 2024 (Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) is pleased to announce that during its Annual General Meeting held on May 8, 2024, shareholders approved all agenda items presented, including the expansion of the Management Board from three to four members.

Key Points: 
  • Amsterdam, 8 May 2024 (Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) is pleased to announce that during its Annual General Meeting held on May 8, 2024, shareholders approved all agenda items presented, including the expansion of the Management Board from three to four members.
  • Mr. Michael Connor was appointed to the Management Board as Chief Corporate Development Officer for a term of four years, with effect from May 8, 2024.
  • During the meeting, Mr. Jackson Dunckel was reappointed as Chief Financial Officer for an additional term of four years, beginning May 8, 2024.
  • During the meeting, Ms. Dagmar Bottenbruch was appointed to the Supervisory Board as an independent member for a term of four years, beginning May 8, 2024.